News | 11 November 2021
Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
The consideration for the acquisition is US $ 2.25 million
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The company has operations in North America, Asia, and Europe,
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
It is the world’s first DNA-based Covid vaccine
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Biocon Biologics and Viatris co-developed the products
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
Subscribe To Our Newsletter & Stay Updated
